Serum thymidine kinase 1 reflects the progression of premalignant and malignant tumors during therapy

Molecular Medicine Reports

Volumn 1, Issue 5, 2008, Pages 705-711

  Xu, Xiao Hong ^a   Zhang, Yi Min ^a   Shu, Xin Hua ^a   Shan, Lu Hu ^a   Wang, Zi Wei ^b   Zhou, Yong Lie ^c   Wen, Huai Kai ^d   He, Fan ^e   He, Ellen ^f   Skog, Sven ^f,g  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d WENZHOU MEDICAL UNIVERSITY   (China)

^e Zhejiang Centre for Disease Control   (China)

^f KAROLINSKA INSTITUTE   (Sweden)

^g NONE   (Sweden)

Author keywords

Adenocarcinoma; Cancer; Serum; Squamous cell carcinoma; Thymidine kinase 1

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; THYMIDINE KINASE 1;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BENIGN TUMOR; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CARCINOMA; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; INTESTINE CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PANCREAS CARCINOMA; PATIENT MONITORING; PRECANCER; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; UTERINE CERVIX CARCINOMA;

EID: 69449104988     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000017     Document Type: Article

References (35)

1. Tumor Markers. Eissa S (ed). Chapman & Hall, New York, pp94-102, pp134-137, 1998.
2. Tocchi A, Costa G, Lepre L, Liotta G, Mazzoni G, Cianetti A and Vannini P: The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol 124: 450-455, 1998. (Pubitemid 28407579)
3. Ychou M, Duffour J, Kramar A, Gourgou S and Grenier J: Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 16: 105-110, 2000. (Pubitemid 32591564)
4. Dehaghani AS, Ghiam AF, Hosseini M, Mansouri S and Ghaderi A: Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women. Pathol Oncol Res. 13: 360-364, 2007. (Pubitemid 351287319)
5. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM and Poon RT: Biology of hepatocellular carcinoma. Ann Surg Oncol 15: 962-971, 2008.
6. Ulmert D, Cronin AM, Bjork Th, O'Brien MF, Scardino PT, Eastam JA, Becker Ch, Berglund G, Vickers AJ and Lija H: Prostatic-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a casecontrol study. BMC Med 6: 6, doi: 10.1186/1741-7015-6-6, 2008.
7. Cheung KL, Evans AJ and Robertson JF: The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat 67: 273-278, 2001. (Pubitemid 32803533)
8. Hwa HL, Kuo WH, Chang LY, Wang MY, Tung TH, Chang KJ and Hsieh FJ: Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract 14: 275-280, 2008.
9. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.
10. He Q, Skog S and Tribukait B: Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumours. Cell Prolif 24: 3-14, 1991.
11. Kauffman MG and Kelly TJ: Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 11: 2538-2546, 1991.
12. Ke PY and Chang ZF: Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 24: 514-526, 2004.
13. He Q, Wang N, Skog S, Ericsson S and Tribukait B: Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70: 117-124, 1996. (Pubitemid 26177210)
14. Gronowitz JS, Hagberg H, Kallander CF and Simonsson B: The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47: 487-495, 1983.
15. O'Neill KL, Abram WP and McKenna PG: Serum thymidine kinase levels in cancer patients. Ir J Med Sci 155: 272-274, 1986.
16. Gronowitz JS, Bergström R, Nôu E, Påhlman S, Brodin O, Nilsson S and Källander CF: Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 66: 722-732, 1990.
17. Bresnick E, Mayfield ED Jr, Liebelt AG and Liebelt RA: Enzyme patterns in a group of transplantable mouse hepatomas of different growth rates. Cancer Res 31: 743-751, 1971.
18. He Q, Skog S, Fornander T, Johansson H, Johansson U, Hu G, Rutqvist LE and Skog S: Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following operation of early breast cancer patients. Anticancer Res 26: 4753-4760, 2006.
19. Broët P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, Asselain B, Martin PM and Spyratos F: Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19: 2778-2787, 2001. (Pubitemid 32538185)
20. Foekens JA, Romain S, Look MP, Martin PM and Klijn JG: Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61: 1421-1425, 2001. (Pubitemid 34292567)
21. He Q, Zhang P, Zou L, Li HX, Wang XQ, Zou S, Fornander T and Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep 14: 1013-1019, 2005.
22. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M. AJCC Cancer Staging Manual. Springer-Verlag, New York, 2002.
23. Wu CJ, Yang RJ, Zhou J, Bao S, Zou L, Mao YR and He Q: Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277: 157-169, 2003. (Pubitemid 36694382)
24. Sauer H and Wilmanns W: Thymidine kinase. In: Method of Enzymatic Analysis. Vol 3. Bergmeyer HU, Bergmeyer J and Grassl M (eds). Verlag Chemie, Weinheim, Deerfield Beach, Florida, pp 468-473, 1983.
25. He Q, Zou L, Zhang PA, Lui JX, Skog S and Fornander T: The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Int J Biol Markers 15: 139-146, 2000. (Pubitemid 30389361)
26. Zou L, Zhang PG, Zou S, Li Y and He Q: The half-life of cytosolic thymidine kinase in serum by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 17: 135-140, 2002.
27. Li HX, Zhang S, Lei DS, Wang XQ, Skog S and He Q: Serum thymidine kinase 1 (STK1) is a prognostic and monitoring factor in patients with non-small-cell lung cancer. Oncol Rep 13: 145-149, 2005.
28. Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, Luo P, Zhang W and He Q: Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15: 455-461, 2006.
29. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. In: WHO Classification of Tumours. Tavassoli FA and Devilee P (eds). IARC Press, Lyon, pp63-73, 2003.
30. General and Systematic Pathology. 4th edition. Underwood JCE (ed). Churchill Livingstone, Edinburgh, 2004.
31. Gronowitz JS, Källander FR, Diderholm H, Hagberg H and Pettersson U: Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 33: 5-12, 1984.
32. Tanaka K, Sishido T, Morimoto M, Inoue S, Takamura Y and Masumura M: Elevated serum thymidine kinase activity in patients with acute viral hepatitis. Gastroenterol Jpn 28: 51-55, 1993. (Pubitemid 23114157)
33. Turriziani O, Butera O, Gianotti N, Parisi SG, Mazzi R, Girardi E, Iaiani G, Antonelli L, Lazzarin A and Antonelli G: Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. AIDS 19: 473-479, 2005. (Pubitemid 40515850)
34. Sandström H, Wahlin A, Eriksson M and Bergström I: Serum thymidine kinase in congenital dyserythropoietic anaemia type III. Br J Haematol 87: 653-654, 1994. (Pubitemid 24230043)
35. Yang L, Parkin DM, Ferlay J, Li L and Chen Y: Chines cancer incident rate: estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14: 243-250, 2005.